• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Why Daiichi Sankyo Shares Are Up 5.2% And What's Next

    Simply Wall St·10/31/2026 09:36:34
    Listen to the news
    • Daiichi Sankyo reaffirmed its full year 2026 guidance, targeting JPY 2.34 trillion in global revenue and JPY 320.0 billion in operating profit, alongside fresh oncology and cardiovascular product milestones in Europe and early stage pipeline progress.
    • The combination of strong demand for Enhertu and Datroway, new EU approvals and applications, and continued DXd ADC pipeline investment highlights how much Daiichi Sankyo is leaning on oncology execution while carrying sizable research and manufacturing cost commitments.
    • We will now examine how Daiichi Sankyo's reaffirmed FY2026 guidance might reshape its investment narrative around oncology driven earnings.
    Spot oncology-led momentum like Daiichi Sankyo's and compare it with a hand picked field of other potential breakouts across 10 healthcare AI stocks.

    Daiichi Sankyo Company Investment Narrative Recap

    To own Daiichi Sankyo Company, you need to believe its concentrated oncology portfolio can support the current spending profile while the broader pipeline matures. The reaffirmed FY2026 targets of JPY 2.34t in revenue and JPY 320.0b in operating profit indicate that management still regards the current product mix and cost base as workable.

    In the near term, the key swing factor remains execution on Enhertu and Datroway, together with managing high CMO fees and R&D outlays. The biggest risk is that elevated costs and any product specific issues keep margins under pressure, even if top line guidance is maintained.

    The fresh EU approval for Enhertu in adjuvant HER2 positive early breast cancer appears most relevant to this guidance update. It brings an immediate US$75m milestone from AstraZeneca and gives Daiichi Sankyo more HER2 exposure in a potentially earlier line setting, where sales in most EU territories are booked by the company.

    For an investor, that approval highlights both the opportunity and the concentration risk. Oncology execution becomes even more central to the catalyst path, while any safety, competitive, or pricing pressure on Enhertu would feed directly into the reaffirmed FY2026 earnings framework.

    Daiichi Sankyo Company's current analyst narrative points to ¥2,718.7b in revenue and ¥348.3b in earnings by 2029, based on 6.9% yearly revenue growth and an earnings increase of roughly ¥85.4b from current earnings of ¥262.9b.

    Uncover how Daiichi Sankyo Company's fair value indicates a 48% potential upside to its current price that could narrow quickly if oncology momentum holds.

    TSE:4568 1-Year Stock Price Chart
    TSE:4568 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate view focuses on cost risk rather than oncology upside. The most optimistic analysts were already pencilling in ¥3,152.0b of revenue and ¥476.5b of earnings by 2029 for Daiichi Sankyo Company, before this latest guidance reset. You can see how strongly opinions differ, and why these fresh oncology and cardiovascular updates may shift those forecasts again.

    Explore 2 other Daiichi Sankyo Company fair value estimates, including one that suggests as much as 118% upside from the current price.

    Decide For Yourself

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Looking For More Investment Ideas Beyond Daiichi Sankyo Company?

    If the oncology story at Daiichi Sankyo Company has sharpened your thinking, use that momentum to scan a broader field of opportunities. The Simply Wall St Screener helps you quickly filter for different types of businesses that match your risk tolerance and income goals.